The case suggests lung transplantation can be a feasible option for patients with lung involvement. A new case report is adding complexity to scientists’ understanding of a rare lysosomal storage ...

The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...

Brensocatib is the first approved therapy for non–cystic fibrosis bronchiectasis and the first dipeptidyl peptidase 1 inhibitor for neutrophil-mediated diseases. The ASPEN trial showed brensocatib ...

Please provide your email address to receive an email when new articles are posted on . The population-based cohort study included 3,858,422 participants from the 2009 National Health Screening ...

LOS ANGELES — For patients with non–cystic fibrosis bronchiectasis, an investigational inhaled powder form of ciprofloxacin can significantly reduce the frequency of exacerbations, results from the ...

MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...

Brensocatib, the first FDA-approved medication to treat non-cystic fibrosis bronchiectasis, can reduce symptoms of the chronic lung condition by targeting inflammation.